Acute leukemias

Acute Leukemias: High-Yield Blast Pathologies & Diagnostics

Acute leukemias are aggressive, neoplastic proliferations of immature hematopoietic cells, known as blasts, within the bone marrow. The defining diagnostic hallmark for acute leukemia is a bone marrow blast count of ≥ 20%. This rapid clonal expansion crowds out normal hematopoiesis, leading to acute marrow failure and fatal systemic complications if left untreated.

1. Pathophysiology: Marrow Crowding

As neoplastic blasts accumulate, they mechanically choke out normal stem cell niches. This results in an abrupt-onset pancytopenia that accounts for the core clinical presentation:

• Anemia: Presents as profound fatigue, pallor, and dyspnea.
• Thrombocytopenia: Manifests as petechiae, purpura, epistaxis, and mucosal bleeding.
• Functional Neutropenia: While the total White Blood Cell (WBC) count can be low, normal, or massively elevated (up to > 100,000/μL), the circulating cells are non-functional blasts. This leaves patients highly susceptible to severe, life-threatening opportunistic infections.

2. Acute Lymphoblastic Leukemia (ALL)

ALL stems from the malignant transformation of immature pre-B or pre-T lymphocytes. It is the **most common malignancy in children** and is highly associated with Down syndrome (specifically presenting *after* the age of 5).

ALL Subtype	Immunophenotype & Genetics	High-Yield Presentation Clinical Features
B-ALL (~85% of cases)	• Markers: **TdT+** (DNA polymerase marker of lymphoblasts), **CD10+, CD19+, CD20+**. • ** translocation:** Excellent prognosis; seen mostly in children. • ** translocation (Philadelphia+):** Poor prognosis; seen more commonly in adults.	Highly responsive to conventional chemotherapy. Requires mandatory **CNS prophylaxis** (intrathecal methotrexate) because blasts easily cross the blood-brain barrier and nest in the meninges or testes.
T-ALL (~15% of cases)	• Markers: **TdT+**, **CD2 through CD8** (lacks CD10/CD19).	Classically presents in adolescents as a massive mediastinal (thymic) mass. Can lead to Superior Vena Cava (SVC) syndrome or tracheal compression.

3. Acute Myeloid Leukemia (AML)

AML involves the neoplastic proliferation of immature myeloid precursors. It is predominantly a disease of **older adults (median age ~65)**. It can arise de novo or secondarily from pre-existing Myelodysplastic Syndromes (MDS) or alkylating chemotherapy exposure.

• Diagnostic Profiling: Myeloblasts are **TdT- negative** and express **CD13+, CD33+, and CD34+**. They are cytochemically positive for **Myeloperoxidase (MPO)**.
• Microscopic Smear Finding: The presence of **Auer rods**—crystalized aggregates of MPO visible as pink/red needle-like cytoplasmic inclusions—is completely pathognomonic for AML.
• Subtype Associations: Acute monocytic leukemia (an AML variant) characteristically causes **gingival hyperplasia**, where leukemic monoblasts infiltrate the gum tissues.

4. Acute Promyelocytic Leukemia (APL) — The Ultimate Board Favorite

APL (formerly AML M3) represents a medical emergency that must be recognized instantly. Granular promyelocytes accumulate and threaten catastrophic vascular collapse.

• Cytogenetics: Driven by a chromosomal translocation. This fuses the Retinoic Acid Receptor Alpha (RARA) gene on chromosome 17 with the PML gene on chromosome 15. The resulting chimeric protein blocks myeloid differentiation at the promyelocytic stage.
• The Complication: Promyelocytic blasts are packed with coarse granules containing tissue factor-like procoagulants. Upon cell breakdown or activation, they trigger rapid, disseminated **Disseminated Intravascular Coagulation (DIC)**.
• Targeted Therapy: Treatment circumvents standard cytotoxic mechanisms by using **All-Trans Retinoic Acid (ATRA)** and arsenic trioxide. ATRA binds the mutated RARα receptor, forcing the malignant promyelocytes to differentiate into mature, short-lived neutrophils, bypassing DIC risks.

5. Differentiating Lymphoblasts vs. Myeloblasts

Distinguishing the blast lineage underpins all initial diagnostic decision-making: